Company intelligence / Profile preview

Respirix

San Francisco, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Respirix has developed a proprietary, non-invasive handheld device ("Cardiospire") that monitors subtle pressure waves in the airway to assess cardiac function in congestive heart failure patients. The system transmits data to the cloud for algorithmic analysis to detect early signs of decompensation before symptoms appear. No published clinical trial results are available as of the latest information.

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital health platform (non-pharmacological therapy)
Industry: Physiological Monitoring

Partnerships

MedTech Innovator accelerator program participant

Beyond the preview

Go deeper on Respirix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respirix.

Explore the full profile